This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Oncodesign Precision Medicine's Median PS Value or its related term are showing as below:
XPAR:ALOPM's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.645 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Oncodesign Precision Medicine (XPAR:ALOPM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Oncodesign Precision Medicine's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.343
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine Median PS Value Related Terms
Oncodesign Precision Medicine Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine Median PS Value Chart
XPAR:ALOPM vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine (XPAR:ALOPM) has a Median PS Value of €0.00 as of Jul. 12, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 278 companies in the Biotechnology industry.
Is Oncodesign Precision Medicine's Median PS Value too high?
Oncodesign Precision Medicine's current Median PS Value is €0.00. Based on the distribution chart, Oncodesign Precision Medicine ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 278 companies for Median PS Value. This places Oncodesign Precision Medicine in the lower half of its industry. The industry median Median PS Value is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.29, compared to a current price of €0.34 — trading 18.3% above its estimated fair value. The current Median PS Value is €0.00. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Median PS Value is €0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.34 is trading 18.3% above its estimated GF Value™ of €0.29.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for XPAR:ALOPM:
Median PS Value: €0.00
GF Value™: €0.29 vs. price of €0.34 (18.3% above fair value)
No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score
Get the complete analysis for XPAR:ALOPM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALOPM has been successfully added to your 
